Revelyx Bio Secures Tens of Millions in Series A Funding to Advance World’s First Recombinant Botulinum Toxin Type A Liquid Formulation

(Shanghai, January 9, 2026) – Revelyx Bio Inc. (Revelyx Bio) today announced the completion of its Series A financing round, raising tens of millions of U.S. dollars. The round was exclusively led by NRL Capital. The proceeds will be primarily used to advanceWorld's FirstGlobal Market Approval and Commercial Expansion of the Recombinant Botulinum Toxin Type A Liquid Formulation Pipeline.

Revelyx Bio, a company incorporated in Delaware, United States, in 2025, has entered into an exclusive licensing agreement with a Chinese biotech firm for its independently developed pipeline of liquid formulations of recombinant botulinum toxin type A. The agreement grants Revelyx Bio exclusive licensing rights to the licensed products in overseas markets, excluding mainland China, the Hong Kong Special Administrative Region, and the Macao Special Administrative Region. The licensed product isinLate-Stage Clinical Developmentof recombinant botulinum toxin type A liquid formulation, which is currently undergoing Phase II clinical trials in Australia for the indication of glabellar lines.

NRL Capital’s Healthcare and Medical Team stated: “The world's first we invested inRecombinant Type A Botulinum Toxin Liquid Formulation Products will bring global users a novel anti-aging and medical experience characterized by superior efficacy, safety and reliability, low immunogenicity, overcoming drug resistance, precise targeting, and ease of use. It is an honor toParticipating in the investment of Revelyx Bio, this collaboration will lay a solid foundation for advancing clinical and commercial promotion globally. We are firmlyBullish on the first recombinant botulinum toxin type A liquid formulationglobal competitiveness and will continue to support the long-term future development of Revelyx Bio.”

NRL Capital is an investment and fund management platform that leverages top-tier domestic and international industrial resources alongside long-term capital. It features an integrated framework combining three core capabilities—fund of funds, direct investment, and private equity secondary investments—and operates with a dual-drive strategy utilizing both onshore RMB and offshore USD. The firm focuses deeply on key sectors including healthcare, semiconductors and intelligent manufacturing, new energy and carbon neutrality, and consumer technology.